Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 565.

https://doi.org/10.1182/blood-2025-565

Published: 2025

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 7090.

https://doi.org/10.1182/blood-2025-7090

Published: 2025

Journal Articles

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Blood (2025) 146 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2025-4498

Published: 2025

Journal Articles

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

Blood (2025) 146 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2025-2396

Published: 2025

Journal Articles

CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies

Xiaoli Mi, Dennis Yuan, Nicholas Midler, Alexander Lewis, Rebecca Murray, Alyssa Indart, Kenyon Weis, Olga Shestova, Susan DeWolf, Jae Park, Omar Abdel-Wahab, Saar Gill, Dan Avi Landau

Blood (2025) 146 (Supplement 1): 499.

https://doi.org/10.1182/blood-2025-499

Published: 2025

Journal Articles

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2025-3365

Published: 2025

Journal Articles

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Cecilia Yeung, Olga Sala Torra, Brent Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron Gerds, Susan O'Brien, Jane Liesveld, Megan Othus, Mark Litzow, Richard Stone, Jerald Radich, Harry Erba

Blood (2025) 146 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2025-3343

Published: 2025

Journal Articles

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 6296.

https://doi.org/10.1182/blood-2025-6296

Published: 2025

Journal Articles

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3902.

https://doi.org/10.1182/blood-2025-3902

Published: 2025

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 3711.

https://doi.org/10.1182/blood-2025-3711

Published: 2025

Journal Articles

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Heather Landau, Shahzad Raza, Aaron Rosenberg, Jeffrey Zonder, Raymond Comenzo, Vaishali Sanchorawala, Michaela Liedtke, Amandeep Godara, Michael Rosenzweig, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu

Blood (2025) 146 (Supplement 1): 696.

https://doi.org/10.1182/blood-2025-696

Published: 2025

Journal Articles

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

Claire Roddie, Jae Park, Eleni Tholouli, Karamjeet Sandhu, Paul Shaughnessy, Pere Barba, Manuel Guerreiro, Deborah Yallop, Aaron Logan, Mehrdad Abedi, Pierre Lao-Sirieix, Ping Wang, Wolfram Brugger, Bijal Shah, Anthony Hunter, Daniel Deangelo, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2025-5118

Published: 2025

Journal Articles

BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 4492.

https://doi.org/10.1182/blood-2025-4492

Published: 2025

Journal Articles

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 1079.

https://doi.org/10.1182/blood-2025-1079

Published: 2025

Journal Articles

Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization

Yannis Valtis, Benjamin Frost, David Nemirovsky, Andriy Derkach, Kuo-Kai Chin, Meira Yisraeli Salman, Leora Boussi, Natalia Tijaro Ovalle, Eytan Stein, Emilie Baxter, Mark Geyer, Marlise Luskin, Daniel Deangelo, Jae Park, Evan Chen

Blood (2025) 146 (Supplement 1): 1078.

https://doi.org/10.1182/blood-2025-1078

Published: 2025

Journal Articles

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Blood (2025) 146 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2025-2715

Published: 2025

Journal Articles

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Blood (2025) 146 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2025-2710

Published: 2025

Journal Articles

Endogenous regulation of inflammatory response as a determinant of durable remission without stem cell transplant following brexucabtagene autoleucel (Brexu-cel) therapy in ALL

Sabina Adhikary, Colleen Schweitzer, Daqin Mao, Rita Damico Khalid, Rhine Shen, Jae Park

Blood (2025) 146 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2025-1588

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy

Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Endogenous regulation of inflammatory response as a determinant of durable remission without stem cell transplant following brexucabtagene autoleucel (Brexu-cel) therapy in ALL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only